Choose your Region

Are you sure you want to proceed?

You will be leaving the Cook Medical website that you were viewing and going to a Cook Medical website for another region or country. Not all products are approved in all regulatory jurisdictions. The product information on these websites is intended only for licensed physicians and healthcare professionals.

Take a different approach to hemostasis

Acute gastrointestinal bleeding can be a difficult and challenging condition. For more than 30 years, our wide selection of time-tested hemostasis tools have provided physicians with dependable solutions that help meet a variety of clinical needs. These devices include:

Instinct Plus: the newest addition to our hemostasis portfolio

Also known as an endoclip, the Instinct Plus Endoscopic Clipping Device is indicated for hemostasis and additional endoscopic applications, such as defect closure, endoscopic marking, and affixing esophageal self-expanding metal stents to the esophageal wall. Check out the resources below to see how these devices could help you to help your patients.


Connect with us!

Looking for training or your local contact? Let us help.

    By clicking Submit, you agree to the terms and conditions for collecting and processing your personal information, as included in our customer data privacy notice. This form is intended for US-based physicians only.

    Clinical data demonstrate Hemospray’s high success rates

    Unlike traditional therapies, Hemospray is a nonthermal, nontraumatic, noncontact modality that doesn’t require the precise targeting of other endoscopic devices. The Hemospray Endoscopic Hemostat creates a mechanical barrier over bleeding sites, and it has demonstrated successful results in a wide range of nonvariceal GI bleeds.

    The publication of the largest multicenter international registry of Hemospray patients investigates the efficacy of Hemospray as a monotherapy, as part of a combination therapy, and as a rescue therapy.1 The registry shows that high hemostasis rates are achieved with Hemospray and that rebleed rates are in keeping with or lower than predicted rates.1

    Learn more about the registry:

    The information below was excerpted from a blog post available here:

    Outcomes from an international multicenter registry of patients with acute gastrointestinal bleeding undergoing endoscopic treatment with Hemospray1

    Prospective data were collected from 314 patients across 12 centers. “These data show high rates of immediate hemostasis overall and in all subgroups.” “Hemospray was effective in achieving primary hemostasis with an overall hemostasis rate of 89.5%.”

    Explore our Hemostasis devices

    Instinct Plus reengineered

    Instinct Plus reengineered

    The Instinct Plus Endoscopic Clipping Device—now with an updated indication for use—can be deployed simply in one step.

    See what’s new

    Hemospray NTAP approval

    Hemospray NTAP approval

    When used in an inpatient or acute-care setting, Hemospray Endoscopic Hemostat is approved for a new technology add-on payment by the Centers for Medicare & Medicaid Services.

    Learn More

    A different approach to Hemostasis (symposium)

    A different approach to Hemostasis (symposium)

    Dr. Rehan Haidry and Dr. Mohamed Hussein discuss the latest clinical data on the use of Hemospray Endoscopic Hemostat in hemostasis.

    Watch Symposium

    1. Alzoubaidi D, Hussein M, Rusu R, et al. Outcomes from an international multicenter registry of patients with acute gastrointestinal bleeding undergoing endoscopic treatment with Hemospray. Dig Endosc. 2020;32(1):96–105.